The corrective action of original cholesterol oxidase preparation: in vitro and in vivo use

Summary Atherogenic dyslipoproteinemia (DLP) is one of the modifiable risk factors of atherosclerosis (AS). For the primary prevention of DLP and reduce the risk of progression of the AS, it is necessary to use low cholesterol (Ch) foods and apply modern effective lipid-lowering agents that improve the blood lipid profile. Relevant is the search for various biologically active compounds that correct of lipids in DLP. The original preparation of cholesterol oxidase enzyme (PChO) of microbial origin was the subject of this study. In vitro experiments evaluated the ability of PChO to actively bind cholesterol in food. To assess the effect of PChO under conditions of moderate nutritional DLP, in vivo experiments were carried out in three species of animals (rats, guinea pigs, rabbits). It is established that when modeling DLP, the studied agent PChO when administered orally has a pronounced hypolipidemic effect. It is noted that under these conditions, after applying PChO, the disturbed blood lipid spectrum is significantly improved. When analyzing the results of ultracentrifugation of the blood serum of experimental animals, a decrease in the content of atherogenic (LP)–VLDL, LDL, and a positive increase in the concentration of antiatherogenic HDL, capable of accepting Ch were detected.